Testosterone Therapy for Pubertal Delay in Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy Clinical Trial

Official title:

Observational Study of Clinical Outcomes for Testosterone Treatment of Pubertal Delay in Duchenne Muscular Dystrophy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02571205
• Other study ID #: 2015-003195-68
• Status: Completed
• Start date: November 2015
• Est. completion date: March 2019

Study information

• Verified date: April 2021
• Source: Newcastle-upon-Tyne Hospitals NHS Trust
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

"Observational study of clinical outcomes for testosterone treatment of pubertal delay in Duchenne Muscular Dystrophy" is a single centre observational study that aims to follow the progress of 20 adolescents with Duchenne Muscular Dystrophy (DMD) and delayed puberty who are treated by the Newcastle muscle team, as they are treated with testosterone to induce puberty. The participants will all be treated with the standard stepwise regimen of testosterone injections every 4 weeks and data will be collected to help determine the effectiveness and tolerability of the current treatment regimen. The investigators will use the data to explore the effect of testosterone on pubertal development, growth, muscle strength and function, bone mineral density and body composition and characterise any side effects. Semi-structured interviews will also be carried out to learn the boys' views on the tolerability of the regimen. The study will last up to a maximum of 27 months in total for each participant, but may be less if they are happy with pubertal development before this time. It is important to do this study because from the investigator's limited experience in this group, testosterone treatment seems to be well liked and tolerated but the best treatment regimen to use remains unknown and there is no current consensus. It is not currently part of the standard of care in DMD but it would be important to include it if this study can show that it is an effective treatment for pubertal delay.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 15
• Est. completion date: March 2019
• Est. primary completion date: February 2019
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 12 Years to 17 Years

Eligibility

Inclusion Criteria:

• A molecular diagnosis of Duchenne Muscular Dystrophy.

• Males aged between 12 and 17 years of age at time of first dosing

• Prepubertal (Tanner stage 1, testicular volume <4 mls, initial testosterone level of <2.0 nmol/l)

• Subjects are receiving the standard of care for DMD as recommended by the NorthStar UK and TREAT-NMD guidelines

• Patients are capable of sitting upright in a wheelchair for at least an hour

• Patients have stable respiratory function. Artificial ventilation with either Bipap/continuous positive airways pressure (CPAP) or tracheostomy is not a contraindication to the study.

• Informed consent/assent signed by the patient (or parent/guardian if under 16 years of age)

Exclusion Criteria:

• Severe learning difficulties that would preclude them from cooperating with examination.

• Anticipated surgery during the study period.

• Symptomatic cardiac failure.

• Participants/families who may have emotional or psychological problems if recruited to a study

• Hypersensitivity to the active substance or to any of the excipients, including arachis oil or derivatives (including hypersensitivity and allergy to peanuts or soya.)

• Any contra-indication to receiving an intramuscular injection

• Any additional chronic disease that affects androgen production

• Anti-coagulant therapy

• If participation in the study is not recommended in the opinion of the investigators

Related Conditions & MeSH terms

• Duchenne Muscular Dystrophy
• Muscular Dystrophies
• Muscular Dystrophy, Duchenne
• Puberty, Delayed

Intervention

Drug:
• Sustanon (testosterone)
Standard incremental regimen of Sustanon

Locations

Country	Name	City	State
United Kingdom	Institute of Genetic Medicine	Newcastle Upon Tyne

Sponsors (1)

Lead Sponsor	Collaborator
Newcastle-upon-Tyne Hospitals NHS Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Total score in the Treatment Satisfaction Questionnaire for Medication (TSQM)		2 years
Secondary	Subject's reported effectiveness of testosterone therapy as assessed by semi-structured interviews pre and post treatment		2 years
Secondary	Total score in Northstar Ambulatory Assessment or Performance of the Upper Limb if non-ambulant		2 years
Secondary	Z-score from Bone mineral adjusted density of the lumbar spine and total body (minus head) using Dual Xray Absorptiometry (DXA)		2 years
Secondary	Percentage of body mass assessed by DXA		2 years
Secondary	Osteocalcin level, measured by blood test		2 years
Secondary	P1NP level, measured by blood test		2 years
Secondary	Percentage fat fraction as assessed by muscle Magnetic Resonance Imaging (MRI) of upper and lower limbs		2 years
Secondary	Pubertal staging assessed using Tanner staging and testicular volume		2 years
Secondary	Bone age as assessed by wrist and hand X-Ray		2 years
Secondary	Hormonal assessment of pubertal staging using testosterone level		2 years
Secondary	Forced vital capacity, measured by spirometry		2 years
Secondary	Cardiac function, assessed by Electrocardiogram (ECG) and echo		2 years